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Progressive supranuclear palsy (PSP) is a neurodegenerative 
disorder associated with neuroglial accumulation of 4-repeat 
tau protein [2]. Kovacs et al. [1] have recently proposed a 
new semi-quantitative six-stage system to categorise the 
severity of PSP pathology. Importantly, the system reduces 
reliance on regions with high risk of concomitant pathology 
and focusses on cell type-specific tau-pathology.
Here, we test the new PSP pathology staging system in 
an independent series of 35 PSP cases and test the potential 
association between pathology stage and clinical severity 
at death. We include tissue from 35 people with a clinical 
diagnosis of PSP (including N = 25 with Richardson’s syn-
drome and N = 10 with other phenotypes; Movement Dis-
order Society 2017 criteria; Supplementary table 1, online 
resource). Donors had attended longitudinal clinical studies 
at the Cambridge Centre Parkinson-plus including assess-
ment of clinical severity by the PSP rating scale (PSPRS) 
and cognitive performance by the revised Addenbrooke’s 
Cognitive Examination (ACE-R). The left brain hemisphere 
was available for pathological evaluation (Supplementary 
methods, online resource) and following the guidelines from 
Kovacs et al. we rated regional tau cytopathology focussing 
on astrocytic tau inclusions in striatum (STR), frontal and 
occipital cortices, and neuronal and oligodendroglia tau 
inclusions in globus pallidus (GP), subthalamic nucleus 
(STN), and cerebellum.
First, we selected ten random cases and, in each area, two 
authors independently rated tau pathology following the new 
staging system as described by Kovacs et al. [1]. The raters 
were in agreement in just 45/60 regions (75%). Pallidum, 
cerebellum and occipital lobe had high agreement (≥ 8/10), 
STN and frontal cortex intermediate (7/10), while STR had 
low agreement (4/10). This discrepancy was attributed to 
the lack of operational criteria and individual interpretations 
of the staging system ratings for each area, confounded by 
marked differences between regions in the absolute num-
bers of immunoreactive cells per field. We therefore for-
mulated operational criteria with region-specific thresholds 
see Fig. 1c and Supplementary Fig. 1 (online resource) for 
a visual guide. With the new operational criteria the inter-
rater agreement increased to 88% (52/59 regions), with high 
agreement for GP, STR, frontal cortex, occipital and cerebel-
lum (9/10) and intermediate for STN (7/9). Integrating these 
operational criteria to the new staging system, 91% (32/35) 
of cases fitted readily into one of the six stages (Fig. 1a), 
including 9/10 of the cases with non-Richardson’s pheno-
type (Fig. 1d and e).
We then tested whether the pathology staging was associ-
ated with demographic, age and clinical severity. There was 
no significant association between the pathological stages 
and age or symptom duration (Kruskal Wallis, p > 0.05). The 
interval between death and last assessment of disease sever-
ity (PSPRS and ACE-R) varied from 24 days to 35 months. 
To account for the differences in interval between testing 
and death we took two approaches (1) weighting the anal-
ysis for this time interval (Clinical score ~ PSP pathology 
stage|weight = 1/interval between assessment and death; 
Fig. 1b) and, (2) imputing the PSPRS and ACE-R scores at 
death from longitudinal assessments (imputed score ~ PSP 
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pathology stage; Supplementary Fig. 2a, b and 3, 4, online 
resource). There was a significant association between 
pathology stage and PSPRS, both when weighting for time 
between last testing and death (F(4,25) = 30.0, p = 0.036) 
and using imputed PSPRS scores (F(4,27) = 2.8, p = 0.045). 
There was a significant association between pathology stage 
and cognitive deficit, when weighting the analysis for time 
between testing and death (F(4,27) = 5.09, p = 0.0035), but 
Fig. 1  Validation of pathology staging system for PSP. a Regional 
pathology scores (white to red) and pathology staging (light blue to 
brown). Black tiles indicate a missing region/no stage. Last diagnosis 
based on the movement disorder criteria is shown to the left of the 
tiles. b Pathology stage was correlated with clinical severity PSPRS 
and ACE-R. Individual data points are shown with black dots, box-
plots show median, first and third quartiles, extending whiskers to 
1.5*interquartile range. Grey diamonds show the weighted group 
means, and the size of the points are proportional to the weight in the 
analysis. c Guide for tau pathology rating. d and e Cases with sub-
cortical phenotypes, PSP-P and PSP-PGF, showed minimal pathol-
ogy. Red lines show individual profiles of regional pathology and 
orange fill the average group profiles. Striped lines show concentric 
hexagons representing no to severe (0–3) pathology. PSP progressive 
supranuclear palsy, prob. probable, poss. possible, s.o suggestive of, 
RS Richardson’s syndrome, CBS corticobasal syndrome, SL speech/
language variant, F frontal, PGF progressive gait freezing, P parkin-
sonism, GP globus pallidus, OC occipital cortex, FR frontal cortex, 
CB cerebellum, STR striatum, STN subthalamic nucleus, PSPRS PSP 
Rating Scale, ACE-R revised Addenbrooke’s Cognitive Examination, 
FOV field of view under 40 × objective, A tufted astrocytes, N neu-
ronal tangles and tau positive threads, O coiled bodies, n.s. not sig-
nificant, p > 0.05
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not using imputed ACE-R scores (F(4, 27) = 2.43, p = 0.07). 
Given the small group sizes for stages 2, 3 and 6, post hoc 
analysis were not performed.
Overall, our study supports the validity of the proposed 
PSP pathology staging system proposed by Kovacs et al. [1], 
being easy to implement in the day-to-day neuropathologi-
cal evaluation (and retrospectively) as the regions required 
are routinely sampled for the pathological diagnosis of neu-
rodegenerative disease. The proposed PSP staging schema 
is applicable across the spectrum of clinical PSP subtypes 
with > 90% of cases fulfilling staging criteria. In addition to 
the written description provided by Kovacs et al. we provide 
region-specific quantitative criteria along with a visual guide 
for the rating of tau pathology. Together with high compli-
ance with the staging scheme, our findings suggest that the 
sequential distribution of tau pathology is associated with 
progressive clinical severity in PSP.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00401- 021- 02298-z.
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